Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May-Jun;38(5):1343-1348.
doi: 10.12669/pjms.38.5.5528.

Clinical evaluation of contrast-enhanced CT combined with PET/CT in diagnosis of mediastinal lymph node metastasis of non-small-cell lung cancer

Xiaodong Li  1 , Xiaomeng Zheng  2 , Tianle Zhang  3 , Xi Dong  4 , Jian Su  5
Affiliations

Clinical evaluation of contrast-enhanced CT combined with PET/CT in diagnosis of mediastinal lymph node metastasis of non-small-cell lung cancer

Xiaodong Li et al. Pak J Med Sci. 2022 May-Jun.

Abstract

Objectives: To investigate the clinical value of contrast-enhanced CT combined with PET/CT in the differential diagnosis of mediastinal lymph node metastasis (MLNM) of non-small-cell lung cancer (NSCLC).

Methods: A total of 120 patients with NSCLC combined with mediastinal lymphadenopathy hospitalized in our hospital were selected. All the patients received radical resection of lung cancer and mediastinal lymphadenectomy. After pathological diagnosis, they were divided into MLNM group (malignant group, undergoing contrast-enhanced CT) and non-MLNM group (benign group, receiving contrast-enhanced CT combined with PET-CT). The results were judged by two senior radiologists independently. The results of different scanning methods and postoperative pathology were compared using the t test, χ2 test and Pearson correlation coefficient test.

Results: Compared with the pathological results, contrast-enhanced CT diagnosed 31 cases, with a coincidence rate of 62%, and contrast-enhanced CT combined with PET-CT diagnosed 42 cases, with a coincidence rate of 84%, presenting a statistically significant difference (P = 0.02). Among the 120 patients with lung cancer, pathological examination confirmed MLNM in 50 patients and benign enlargement in 70 patients, contrast-enhanced CT alone detected metastasis in 40 patients and benign enlargement in 80 patients, and contrast-enhanced CT combined with PET-CT detected metastasis in 47 patients and benign enlargement in 73 patients. The sensitivity and accuracy of the latter were significantly higher than those of the former (sensitivity, P = 0.01; accuracy, P = 0.01). With the increase in the malignancy of lymph nodes, the degree of CT enhancement, the concentration of radioactive substances and SUV value increased, showing positive correlations.

Conclusion: Contrast-enhanced CT combined with PET/CT in the diagnosis of MLNM of NSCLC presents higher coincidence rate, sensitivity and accuracy. With the increase in tumor malignancy, the enhancement degree and radioactive substance concentration increase. The two methods are synergistic and complementary in diagnosing MLNM.

Keywords: Contrast-enhanced CT; Differential diagnosis; Mediastinal lymph node metastasis; Non-small-cell lung cancer; PET/CT.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: None.

References

    1. Chassagnon G, Bennani S, Revel MP. Nouvelle classification TNM des cancers du poumon non a petites cellules [New TNM classification of non-small cell lung cancer] Rev Pneumol Clin. 2017;73(1):34–39. doi:10.1016/j.pneumo.2016.12.006. - PubMed
    1. Shi YM, Niu R, Shao XL, Zhang FF, Shao XN, Wang JF, et al. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients. Nucl Med Commun. 2020;41(5):459–468. doi:10.1097/MNM.0000000000001173. - PubMed
    1. Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30(5):787–792. doi:10.1016/j.ejcts.2006.08.008. - PubMed
    1. Moulla Y, Gradistanac T, Wittekind C, Eichfeld U, Gockel I, Dietrich A. Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer:a case control study [published correction appears in J Cardiothorac Surg. 2019 Feb 5;14(1):31] J Cardiothorac Surg. 2019;14(1):11. doi:10.1186/s13019-019-0831-0. - PMC - PubMed
    1. Takahashi Y, Suzuki S, Matsutani N, Kawamura M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer. Thorac Cancer. 2019;10(3):413–420. doi:10.1111/1759-7714.12978. - PMC - PubMed

LinkOut - more resources